# The Pharmacokinetics of P1101 + Ribavirin in Interferon Treatment-Naïve Subjects With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection

> **NCT04774107** · PHASE1 · COMPLETED · sponsor: **PharmaEssentia** · enrollment: 17 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** P1101 + Ribavirin

## Key facts

- **NCT ID:** NCT04774107
- **Lead sponsor:** PharmaEssentia
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-26
- **Primary completion:** 2022-07-18
- **Final completion:** 2022-07-18
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2022-08-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04774107

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04774107, "The Pharmacokinetics of P1101 + Ribavirin in Interferon Treatment-Naïve Subjects With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04774107. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*